Process for producing ethyl esters of polyunsaturated fatty acids

Patent metadata

Field	Value
Publication number	US-9556102-B2
Application number	US-201514600653-A
Country	US
Kind code	B2
Filing date	Jan 20, 2015
Priority date	Jun 15, 2012
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

The present invention relates to a process for producing ethyl esters of polyunsaturated fatty acids, comprising transesterifying triacylglycerols in extracted plant lipid.

First claim

The invention claimed is:

1. A process for producing polyunsaturated fatty acids in an esterified form, the process comprising transesterifying the polyunsaturated fatty acids in triacylglycerols (TAG) in extracted Brassica sp. or Camelina sativa seedoil whose total fatty acid content comprises
(a) a total monounsaturated fatty acid content which comprises oleic acid,
(b) a total saturated fatty acid content which comprises palmitic acid and, if present, myristic acid (C14:0),
(c) a total ω6 fatty acid content which comprises linoleic acid (LA),
(d) a total ω3 fatty acid content which comprises α-linolenic acid (ALA), docosahexaenoic acid (DHA) and one or more of stearidonic acid (SDA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and eicosatetraenoic acid (ETA),
(e) less than 1% myristic acid (C14:0), and
(f) less than 4% eicosatrienoic acid (ETrA),
wherein
(i) a level of DHA of between 7% and 20% is present in the total fatty acid content of the extracted seedoil,
(ii) a level of palmitic acid between 2% and 16% is present in the total fatty acid content of the extracted seedoil,
(iii) a level of oleic acid between 1% and 30% is present in the total fatty acid content of the extracted seedoil,
(iv) a level of linoleic acid (LA) between 4% and 20% is present in the total fatty acid content of the extracted seedoil,
(v) a level of α-linolenic acid (ALA) between 4% and 40% is present in the total fatty acid content of the extracted seedoil,
(vi) the total saturated fatty acid content of the extracted seedoil is between 4% and 25% of the total fatty acid content,
(vii) the ratio of the total ω6 fatty acid content to the total ω3 fatty acid content of the extracted seedoil is between 0.1 and 3.0, and
(viii) the extracted seedoil comprises tri-DHA TAG (TAG 66:18),
thereby producing the polyunsaturated fatty acids in an esterified form.

2. The process of claim 1 in which the extracted seedoil has one or more or all of the following features
i) a level of palmitic acid between 2% and 15% is present in the total fatty acid content of the extracted seedoil,
ii) a level of oleic acid between about 3% and about 30% is present in the total fatty acid content of the extracted seedoil,
iii) a level of linoleic acid (LA) between about 4% and about 17% is present in the total fatty acid content of the extracted seedoil,
iv) a level of α-linolenic acid (ALA) between about 10% and about 35% is present in the total fatty acid content of the extracted seedoil,
v) a level of γ-linolenic acid (GLA) less than 4% is present in the total fatty acid content of the extracted seedoil,
vi) a level of stearidonic acid (SDA) between 0.05% and about 7% is present in the total fatty acid content of the extracted seedoil,
vii) a level of eicosatetraenoic acid (ETA) between 0.05% and about 4% is present in the total fatty acid content of the extracted seedoil,
viii) a level of eicosatrienoic acid (ETrA) between 0.05% and about 2% is present in the total fatty acid content of the extracted seedoil,
ix) the extracted seedoil comprises ω6-docosapentaenoic acid (22:5 Δ4,7,10,13,16 ) in its total fatty acid content,
x) a level of SDA of less than about 0.1%, EPA of less than about 0.1% and ETA of less than about 0.1% is present in its total fatty acid content,
xi) the total saturated fatty acid content in the extracted seedoil is between about 4% and about 20% of the total fatty acid content,
xii) the total monounsaturated fatty acid content in the extracted seedoil is between about 4% and about 35% of the total fatty acid content,
xiii) the extracted seedoil comprises a total polyunsaturated fatty acid content comprising the total ω6 fatty acid content and the total ω3 fatty acid content, wherein the total polyunsaturated fatty acid content in the extracted seedoil is between about 20% and about 75% of the total fatty acid content,
xiv) the total ω6 fatty acid content in the extracted seedoil is less than 20% of the total fatty acid content,
xv) the extracted seedoil comprises new ω6 fatty acids in the total ω6 fatty acid content, wherein the level of new ω6 fatty acids in the extracted seedoil is less than about 10% of the total fatty acid content,
xvi) the total ω3 fatty acid content in the extracted seedoil is between 36% and about 65% of the total fatty acid content,
xvii) the extracted seedoil comprises new ω3 fatty acids in the total ω3 fatty acid content, wherein the level of new ω3 fatty acids in the extracted seedoil is between 9% and about 33% of the total fatty acid content,
xviii) the ratio of the total ω6 fatty acid content to the total ω3 fatty acid content in the extracted seedoil is between about 0.1 and about 0.5,
xix) the extracted seedoil comprises new ω3 fatty acids in the total ω3 fatty acid content and new ω6 fatty acids in the total ω6 fatty acid content, wherein the ratio of the new ω6 fatty acids to the new ω3 fatty acids in the extracted seedoil is between about 0.1 and about 1,
xx) the extracted seedoil has a fatty acid composition based on an efficiency of conversion of oleic acid to DHA of at least about 10%,
xxi) the extracted seedoil has a fatty acid composition based on an efficiency of conversion of LA to DHA of at least about 15%,
xxii) the extracted seedoil has a fatty acid composition based on an efficiency of conversion of ALA to DHA of at least about 17%,
xx) the total fatty acid content in the extracted seedoil has less than 1% C20:1,
xxiv) at least about 70% of the total fatty acid content of the extracted seedoil is esterified in the form of TAG,
xxv) the extracted seedoil comprises diacylglycerol (DAG), and
xxvi) the extracted seedoil comprises less than about 10% free (non-esterified) fatty acids and/or phospholipid.

3. The process of claim 1 , wherein the extracted seedoil comprises one or more sterols.

4. The process of claim 3 , wherein the seedoil comprises less than 10 mg of sterols/g of oil.

5. The process of claim 3 , wherein the seedoil comprises one or more or all of campesterol, Δ5-stigmasterol, eburicol, β-sitosterol, Δ5-avenasterol, Δ7-stigmasterol, and Δ7-avenasterol.

6. The process of claim 3 , wherein the seedoil has a level of cholesterol of less than about 0.5% by weight.

7. The process of claim 1 , wherein the seedoil is canola seedoil.

8. The process of claim 1 , wherein the polyunsaturated fatty acids in an esterified form are ethyl esters of the polyunsaturated fatty acids.

9. The process of claim 8 , wherein the seedoil is a Brassica sp seedoil.

10. The process of claim 1 , wherein a level of eicosapentaenoic acid (EPA) of less than 4% is present in the total fatty acid content of the extracted seedoil.

11. The process of claim 1 , wherein a level of docosapentaenoic acid (DPA) of between 0.05% and 8% is present in the total fatty acid content of the extracted seedoil.

12. The process of claim 1 , wherein the extracted seedoil comprises less than 0.1% ω6-docosapentaenoic acid (22:5 Δ4,7,10,13,16 ) in its total fatty acid content.

13. The process of claim 1 , wherein the most abundant DHA-containing TAG species in the extracted seedoil is DHA/18:3/18:3 (TAG 58:12).

14. The process of claim 1 , wherein a level of docosahexaenoic acid (DHA) of between 8% and 20% is present in the total fatty acid content of the extracted seedoil.

15. The process of claim 1 , wherein a level of docosahexaenoic acid (DHA) of between 10% and 20% is present in the total fatty acid content of the extracted seedoil.

16. The process of claim 1 , wherein a level of docosahexaenoic acid (DHA) of between 11% and 20% is presen

Assignees

• Commw Scient Ind Res Org
• Grains Res & Dev Corp
• Nuseed Pty Ltd
• Nuseed Pty Ltd

Inventors

• Petrie James Robertson
• Singh Surinder Pal
• De Feyter Robert Charles

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P31/18

  for HIV · CPC title